Loading...
Loading...
According to Citi, Isis Pharmaceuticals
ISIS had an uneventful 4Q.
Citi said that ISIS reported total revenues of $26.4M, higher than our estimate of $25.1M and consensus estimate of $22.6M. “EPS for 4Q came in at ($0.14), comparing to our and Street estimates of ($0.13) and ($0.22) respectively. As of December 31, 2010 Co had cash and cash equivalents of $475M.”
Isis Pharmaceuticals closed yesterday at $9.12.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in